Risk factors for discordant immune response among HIV-infected patients initiating antiretroviral therapy: A retrospective cohort study

Muzah, B. P.; Takuva, S.; Maskew, M.; Delany-Moretlwe, S.
November 2012
Southern African Journal of HIV Medicine;Nov2012, Vol. 13 Issue 4, p168
Academic Journal
Background. The therapeutic goal of antiretroviral therapy (ART) is sustained immune recovery and viral suppression. However, some patients experience poor CD4 cell count responses despite achieving viral suppression. Such discordant immune responses have been associated with poor clinical outcomes. Objective. We aimed to determine the prevalence of discordant immune response and explore associated factors in a retrospective cohort of patients attending 2 large public sector clinics, during the 6 months following ART initiation. Methods. Data were analysed from 810 HIV-infected adults initiated on first-line HAART at 2 clinics in Johannesburg, between 1 November 2008 and 31 December 2009. Multivariate logistic regression models were used to estimate adjusted odds ratios (AORs) to determine associations between discordant immune response and clinical and demographic factors. Results. At ART initiation, 65% (n=592) of participants were female, with a mean age of 38.5 years. Median baseline CD4 cell count was 155 cells/mm3, 70% (n=645) of patients had a haemoglobin level >11 g/dl and 88% (n=803) were initiated on stavudine-lamivudine-efavirenz/nevirapine (D4T-3TC-EFV/NVP). Six months after ART initiation, 24% (n=220) of patients had a discordant immune response and 7% (n=67) a discordant virological response. On multivariate analysis, baseline CD cell count ⩾200 cells/mm3 (AOR 3.02; 95% confidence interval (CI) 2.08 - 4.38; p<0.001) and moderate anaemia (8.0 - 9.4 g/dl) at baseline (AOR 2.30; 95% CI 1.25 - 4.59; p=0.007) were independently associated with the development of discordant immune response, after adjustment for education level, World Health Organization (WHO) clinical stage and ART regimen. Conclusions. Discordant immune response following ART initiation was common and associated with baseline anaemia and CD4 cell count in our cohort. Intensive monitoring of at-risk individuals may improve clinical outcomes.


Related Articles

  • Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Nétar Study). Santos, J.; Palacios, R.; González, M.; Ruiz, J.; Márquez, M. // International Journal of STD & AIDS;Oct2005, Vol. 16 Issue 10, p677 

    We undertook a transverse study of 603 HIV outpatients to determine their atherogenic lipid profile (ALP) and cardiovascular risk (CVR) factors. CVR was estimated from the Framingham score. ALP was defined as a total cholesterol to high density lipoprotein (HDL)-cholesterol ratio ≥5 plus...

  • Effect of antiretroviral therapy on clinical and immunologic disease progression in HIV positive children: One-year follow-up study. Patel, Ankur; Trivedi, Sangeeta S.; Chudasama, Rajesh K.; Patel, Priyanka K. // Journal of Family & Community Medicine;Dec2012, Vol. 19 Issue 3, p178 

    Objective: To study the effect of antiretroviral therapy (ART) on clinical, immunologic, and nutritional progression of disease in human immunodeficiency virus (HIV)-infected children for 1 year. Materials and Methods: The study included 54 children aged 1.5-15 years who registered at the ART...

  • Risk Factors for Nevirapine-Associated Rash Among HIV-Infected Patients with Low CD4 Cell Counts in Resource-Limited Settings. Kiertiburanakul, Sasisopin; Sungkanuparph, Somnuek; Charoenyingwattana, Angkana; Mahasirimongkol, Surakameth; Sura, Thanyachai; Chantratita, Wasun // Current HIV Research;Jan2008, Vol. 6 Issue 1, p65 

    Nevirapine (NVP) is commonly used as a component of first-line antiretroviral therapy in resource-limited countries. We aimed to determine the risk factors for NVP-associated rash among HIV-infected patients who were initiated NVP at low CD4 cell counts in a resource-limited setting. A...

  • Endothelial Function in HIV-Infected Persons. Solages, Anthony; Vita, Joseph A.; Thornton, David J.; Murray, Jessica; Heeren, Timothy; Craven, Donald E.; Horsburgh, Jr., C. Robert // Clinical Infectious Diseases;5/1/2006, Vol. 42 Issue 9, p1325 

    Background. Several reports have suggested an increased risk of coronary disease in human immunodeficiency virus (HIV)-infected patients receiving protease inhibitors (PIs). Impaired endothelium-dependent vasodilation is a putative surrogate marker of coronary atherosclerotic disease. Methods....

  • Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study. Chien-Ching Hung; Chin-Fu Hsiao; Jiun-Ling Wang; Mao-Yuan Chen; Szu-Min Hsieh; Wang-Hwei Sheng; Shan-Chwen Chang // International Journal of STD & AIDS;Oct2005, Vol. 16 Issue 10, p673 

    Between June 1994 and May 2003, 93 of 716 (13.0%) HIV-infected patients with a median baseline cell differentiation CD4+ count of 61 × 106 cells/L (range, 1–1206 × 106 cells/L) developed 103 episodes of herpes zoster [HZ], with an incidence of 5.67 per 100 person-years (PY). The...

  • Incidence and Risk Factors for Invasive Pneumococcal Disease in HIV-Infected and Non-HIV-Infected Individuals Before and After the Introduction of Combination Antiretroviral Therapy: Persistent High Risk Among HIV-Infected Injecting Drug Users. Harboe, Zitta Barrella; Larsen, Mette Vang; Ladelund, Steen; Kronborg, Gitte; Konradsen, Helle Bossen; Gerstoft, Jan; Larsen, Carsten Schade; Pedersen, Court; Pedersen, Gitte; Obel, Niels; Benfield, Thomas // Clinical Infectious Diseases;Oct2014, Vol. 59 Issue 8, p1168 

    HIV-infected adults have a substantially high-risk of invasive pneumococcal disease compared to those without human immunodeficiency virus (HIV) infection. The risk was reduced among HIV-infected individuals who were on antiretrovirals and who had favorable markers of immunosuppression, but not...

  • Cystatin C, Adipokines and Cardiovascular Risk in HIV Infected Patients. Falasca, Katia; Ucciferri, Claudio; Mancino, Paola; Di Iorio, Angelo; Vignale, Francesca; Pizzigallo, Eligio; Vecchiet, Jacopo // Current HIV Research;Jul2010, Vol. 8 Issue 5, p405 

    Objectives: To value the role of leptin, adiponectin and cystatin C in HIV infected patients treated with combined antiretroviral therapy (cART) subdivided for cardiovascular risk (CVR). Methods: 56 HIV+ cART treated patients were screened by Framingham score and subdivided in 2 groups: A) 15...

  • NeuroAIDS: An Evolving Epidemic. Power, Christopher; Boissé, Lysa; Rourke, Sean; Gill, M. John // Canadian Journal of Neurological Sciences;May2009, Vol. 36 Issue 3, p285 

    Over 60,000 Canadians are infected with human immunodeficiency virus (HIV). Greater than 50% of these individuals will develop a neurological disorder despite the availability of highly active antiretroviral therapy. HIV causes nervous system disease at all stages of infection with adverse...

  • Risco cardiovascular em doentes infectados por Vírus da Imunodeficiência Humana. Valadas, E.; Sousa, S.; Antunes, F. // RPDI - Revista Portuguesa de Doenças Infecciosas;jan-abr2009, Vol. 5 Issue 1, p07 

    Introduction: Human immunodeficiency virus (HIV) infection, as well as some antiretroviral drugs, has been described to aggravate classical risk factors for cardiovascular disease. Objective: To quantify the cardiovascular risk (CVR) in HIV infected individuals, and to determine the prevalence...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics